



Sanofi Pasteur launches India's first 6-in-1 pediatric vaccine – Hexaxim®

- A fully liquid vaccine protects infants against six World Health Organization (WHO) priority diseases, including polio -

- Improves compliance to immunization schedules by reducing the number of injections -

Mumbai, India, – November 24, 2016 – [Sanofi Pasteur](#), the vaccines global business unit of [Sanofi](#), announced today the launch of India's first innovative ready-to-use fully liquid 6-in-1 vaccine – Hexaxim®. The vaccine, indicated for primary and booster vaccination of infants and toddlers from six weeks to 24 months of age, provides protection against 6 major childhood diseases - diphtheria, tetanus, pertussis (whooping cough), polio, Haemophilus influenza B and hepatitis B.

The burden of the 6 diseases is significant, particularly in infants. Consequently, the WHO and the wide majority of countries around the world recommend vaccination against these diseases. India, under the Universal Immunization Program, also offers protection against these 6 major diseases.ⁱ

Globally, Hexaxim® is the only combination vaccine with acellular pertussis (acP) and inactivated poliovirus vaccine (IPV) to have received a prequalification by the WHO. Today, the vaccine protects infants in more than 60 countries, with 20+ million doses distributed worldwide.

KEY FEATURES OF HEXAXIM®

Fully Liquid, ready to use:

- No reconstitution needed prior to administration, thus avoiding potential risks of contamination and errors
- Reduces administration time

6-in-1 combination:

- Reduces the number of injections;
- Consistently and reliably ensures the right dose of each antigen every time;
- Improves compliance to immunization schedules

Preservative-free:

- Produced using high quality production processes with all antigens fully manufactured by Sanofi Pasteur

Sharing his comments on the launch, Jean-Pierre Baylet, Country Head – Sanofi Pasteur India, Nepal and Sri Lanka, said, *“We are very excited and proud to introduce India's first 6-in-1 combination pediatric vaccine. Hexaxim® brings to life Sanofi Pasteur's mission to improve*



human health by developing superior innovative vaccination solutions against infectious diseases. Given the large influx of patients met by pediatricians in India, Hexaxim® will offer convenience and ensure consistency in administering the right dose of each antigen every single time. At Sanofi Pasteur, with every new vaccine we launch, our aim is to raise the bar of care in vaccination of children.”

Hexaxim®, during its clinical study assessment, was found to be safe and well tolerated as a primary series and booster vaccination in all schedules, countries, and ethnicities tested. Each dose of Hexaxim® takes 24 to 36 months to be manufactured, of which 70% of the time is spent on quality tests. Sanofi Pasteur, a pioneer in the field of pediatric vaccines, has leveraged on its wealth of expertise in manufacturing complex combination vaccines to develop the world’s first fully liquid hexavalent vaccine.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: [SAN](#)) and in New York (NYSE: [SNY](#)).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur produces a portfolio of high quality vaccines that matches its areas of expertise and meets public-health demand. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the



expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Sanofi India

Aparna THOMAS

Tel.: +91 22 28032169

aparna.thomas@sanofi.com

www.sanofi.in

Nikita MERCHANT

Tel.: +91 22 28032112

nikita.merchant@sanofi.com

ⁱ http://www.nhp.gov.in/sites/default/files/pdf/immunization_uip.pdf